Trial · NCT07908485
Implementation Development for Distress Screening in Pediatric Oncology (ID-DISTRESSS)
NCT07908485, Not yet recruiting, Children's Oncology Group
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Implementation Development for Distress Screening in Pediatric Oncology (ID-DISTRESSS). Trials, record NCT07908485. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07908485
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Implementation Development for Distress Screening in Pediatric Oncology (ID-DISTRESSS)
- NCT number
- NCT07908485
- Status
- Not yet recruiting
- Enrollment
- 120 participants, estimated
- Lead sponsor
- Children's Oncology Group
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
- Interventions
- Non-Interventional Study
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | CFIR inner setting characteristics | Up to study completion, up to 1 year | Will assess organizational structural characteristics (physical, IT, and work infrastructure) and available resources (funding, materials, and equipment) that support and deliver distress screening to patients and caregivers as measured by the CFIR Inner Setting measure and semi-structured interview. Descriptive statistics will be used to understand responses across sites. Means and standard deviations, as well as one and two-way tables and figures will be used to summarize and understand survey responses and inter relationships among inner setting, innovation, screening practices, and site characteristics. Survey responses will be described separately for each respondent type to capture the distinct perspectives and experiences of each group. A quasi-deductive approach will be used to analyze the qualitative data, emphasizing first a deductive approach. |
| Primary | CFIR innovation characteristics | Up to study completion, up to 1 year | Will assess clinician/staff representative perceptions of the relative advantage, complexity, and compatibility of EHR-integrated distress screening as measured by the CFIR Intervention Characteristics measure and semi-structured interview. Descriptive statistics will be used to understand responses across sites. Means and standard deviations, as well as one and two-way tables and figures will be used to summarize and understand survey responses and inter relationships among inner setting, innovation, screening practices, and site characteristics. Survey responses will be described separately for each respondent type to capture the distinct perspectives and experiences of each group. A quasi-deductive approach will be used to analyze the qualitative data, emphasizing first a deductive approach. |
| Primary | Informational assessment of current screening practices | Up to study completion, up to 1 year | Will assess availability of psychosocial services, methods and measures used, screening timing, frequency, and repeat screening practices; workflows for responding to positive screens; referral pathways and follow-up procedures; documentation and tracking of screening, referrals, and follow-up activities within the EHR; and metrics used by sites to define and evaluate successful screening programs. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| UG1CA189955 | Children's Oncology Group NCI Community Oncology Research Program (NCORP) Research Base grant | ROTH, MICHAEL E.; POLLOCK, BRAD H | PUBLIC HEALTH INSTITUTE | NATIONAL CANCER INSTITUTE | 2014 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07908485
GET https://conductscience.org/api/trials/v1/NCT07908485/registered